Congress funds overdose prevention tool—no strings, no corporate giveaway

What it does

This bill requires the federal government to develop research and marketing frameworks to help manufacturers create better fentanyl and xylazine test strips, authorizes federal grants to fund distribution of these test strips to first responders and communities, mandates training for first responders on how to use and distribute them, and requires a study on whether test strip availability reduces overdose deaths and increases treatment engagement.

Why we flagged it

The bill's operative mechanism is straightforward: it funds research, training, and distribution of drug-checking test strips as a public health intervention to reduce overdose mortality. No tax carve-outs, no immunity grants, no private beneficiary capture.

What the text implies

• Test strip distribution may normalize drug use in some communities while simultaneously reducing overdose risk — a genuine public health trade-off that the mandated study should illuminate.
• Federal frameworks for test strip authorization may accelerate FDA pathways for harm-reduction diagnostics, potentially creating precedent for other drug-checking technologies (e.g., fentanyl-detection wearables).
• First responder training on test strips may shift naloxone/Narcan distribution models, as responders become equipped to identify adulterants before overdose occurs rather than only after.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill expands access to harm-reduction tools (test strips) that allow people to detect dangerous adulterants in drugs before use, potentially preventing overdose deaths. It imposes no restrictions on citizens' rights or remedies, creates no new liabilities, and funds public health infrastructure with no private carve-outs or immunity grants.

Who stands to gain

• test strip manufacturers (via research frameworks and potential grant-funded procurement)
• harm-reduction nonprofits and community health organizations (via grant funding for distribution)

Named in the bill

Department of Health and Human Services (HHS), National Institutes of Health (NIH), Office of National Drug Control Policy (ONDCP), Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), first responders, substance use disorder treatment providers

Where it stands

1 cosponsor: 1 Republicans.

• Feb 25, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 25, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
• Jun 25, 2026 — Markup held in committee · Congress.gov: “Subcommittee Consideration and Mark-up Session Held”
• Jul 21, 2026 — Reported out of committee · Congress.gov: “Ordered to be Reported by the Yeas and Nays: 48 - 0”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 3 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $5,903,000 in lobbying spend. A filing names 103 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Jasmine Crockett, the sponsor, reported $197,965 in PAC receipts in the 2026 cycle.

• American Medical Association — $5,643,000 on 2 filings
• American Society of Health-system Pharmacists — $260,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.